C4 Therapeutics (CCCC) Free Cash Flow Growth (3y) (2022 - 2026)
C4 Therapeutics (CCCC) Free Cash Flow Growth (3y) (2022 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,725.60 Bn | 68,725.31 Bn | - | -5.05% |
| 2 | Nanobiotix | 1,953.19 Bn | 1,953.13 Bn | - | - |
| 3 | Akari Therapeutics | 1,132.35 Bn | 1,132.35 Bn | - | - |
| 4 | BeOne Medicines | 472.73 Bn | 467.94 Bn | 1.35 Bn | 31.07% |
| 5 | Vertex Pharmaceuticals | 123.52 Bn | 116.27 Bn | 2.59 Bn | 14.71% |
| 6 | Regeneron Pharmaceuticals | 69.74 Bn | 60.99 Bn | 3.31 Bn | -10.65% |
| 7 | Belite Bio | 63.09 Bn | 63.09 Bn | - | - |
| 8 | Argenx Se | 56.42 Bn | 51.24 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.76 Bn | 37.76 Bn | - | - |
| 10 | C4 Therapeutics | 450.09 Mn | 214.42 Mn | - | 3.84% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.84% |
| Dec 31, 2025 | 9.46% |
| Sep 30, 2025 | 0.30% |
| Jun 30, 2025 | 18.63% |
| Mar 31, 2025 | -7.53% |
| Dec 31, 2024 | 11.28% |
| Sep 30, 2024 | -12.24% |
| Jun 30, 2024 | 35.34% |
| Mar 31, 2024 | 10.95% |
| Dec 31, 2023 | -3.36% |
| Sep 30, 2023 | -28.54% |
| Jun 30, 2023 | -9.87% |
| Mar 31, 2023 | -26.44% |
| Dec 31, 2022 | -38.38% |